Development and validation of a three-long noncoding RNA signature for predicting prognosis of patients with gastric cancer

Table 1 Patient characteristics and univariate analysis

Characteristic	n	Disease-free survival			Overall survival
		Time (mo)	P value	F	Time (mo)	P value	F
Age, median, yr			0.14	2.17		0.20	1.72
≥ 60	107	42.46			49.39
< 60	93	50.48			55.79
Gender			0.15	2.10		0.12	2.42
Male	142	43.86			50.23
Female	58	49.58			54.82
Bormann type			0.00	44.98		0.00	43.62
I	15	69.93			69.93
II	88	45.57			51.73
III	94	29.35			36.99
IV	3	15.33			25.00
Tumor size			0.00	28.46		0.00	27.42
≥ 5 cm	87	31.51			39.48
< 5 cm	113	57.46			62.07
Location			0.09	4.91		0.13	4.11
Upper	44	35.22			43.33
Middle	56	49.33			54.92
Low	100	48.92			54.31
Lauren type			0.62	0.96		0.63	0.93
Intestinal	95	45.22			51.26
Mixed	45	41.08			47.06
Diffuse	60	50.23			56.12
Tumor differentiation			0.16	2.00		0.19	1.71
Moderate and well	66	50.80			56.28
Poor	134	44.57			50.74
Vessel invasion			0.00	16.30		0.00	14.73
Yes	59	31.07			38.83
No	141	52.08			57.54
Perineural invasion			0.00	11.24		0.00	11.52
Yes	51	28.01			37.39
No	149	52.14			57.41
TNM stage			0.00	335.89		0.00	360.28
I	42	66.45			66.50
II	47	64.36			68.85
III	109	18.70			28.50
IV	2	5.00			8.50
AC007991.4			0.05	3.77		0.05	3.95
Overexpression	68	53.02			58.07
Weak expression	132	42.70			49.24
AC079385.3			0.00	14.23		0.00	14.71
Overexpression	95	36.26			43.94
Weak expression	105	55.12			59.92
AL109615.2			0.00	10.48		0.02	9.87
Overexpression	113	39.04			46.05
Weak expression	87	56.27			60.90
Model			0.00	21.76		0.00	21.34
High risk	95	37.66			44.46
Low risk	105	53.91			59.27

TNM: Tumor-node-metastasis.